Company registration number 07413237 (England and Wales)
CLINPHARM PLUS LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
CLINPHARM PLUS LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
CLINPHARM PLUS LTD
BALANCE SHEET
AS AT
31 OCTOBER 2024
31 October 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
4
1,044,917
1,310,617
Tangible assets
6
105,151
119,071
Investments
5
200,299
200,299
1,350,367
1,629,987
Current assets
Stocks
195,250
188,159
Debtors
7
3,072,464
2,453,636
Cash at bank and in hand
338,013
428,178
3,605,727
3,069,973
Creditors: amounts falling due within one year
8
(2,200,029)
(1,770,283)
Net current assets
1,405,698
1,299,690
Total assets less current liabilities
2,756,065
2,929,677
Creditors: amounts falling due after more than one year
9
(2,200,505)
(2,410,530)
Provisions for liabilities
(193)
(659)
Net assets
555,367
518,488
Capital and reserves
Called up share capital
3
3
Profit and loss reserves
555,364
518,485
Total equity
555,367
518,488

For the financial year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

CLINPHARM PLUS LTD
BALANCE SHEET (CONTINUED)
AS AT
31 OCTOBER 2024
31 October 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 2 September 2025 and are signed on its behalf by:
Mohammed Azim
Director
Company registration number 07413237 (England and Wales)
CLINPHARM PLUS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
- 3 -
1
Accounting policies
Company information

Clinpharm Plus Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 137 Halesowen Road, Netherton, Dudley, West Midlands, UK, DY2 9PY.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.

1.4
Intangible fixed assets - goodwill

Goodwill is being written off in equal annual instalments over its estimated economic life of 10 years.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% on reducing balance
Motor vehicles
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

The company holds 25% of the share capital in Washwood Heath Healthcare Ltd.

1.7
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

CLINPHARM PLUS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 4 -
1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Government grants

Government small business support grant, NHS Grants and Coronavirus Statutory Sick Pay grants were received during the last year and recognised in other operating income.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
57
55
3
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
87,805
95,272
Deferred tax
Origination and reversal of timing differences
(466)
175
Total tax charge
87,339
95,447
CLINPHARM PLUS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 5 -
4
Intangible fixed assets
Goodwill
£
Cost
At 1 November 2023 and 31 October 2024
2,974,000
Amortisation and impairment
At 1 November 2023
1,663,383
Amortisation charged for the year
265,700
At 31 October 2024
1,929,083
Carrying amount
At 31 October 2024
1,044,917
At 31 October 2023
1,310,617
5
Fixed asset investments
2024
2023
£
£
Other investments other than loans
200,299
200,299
6
Tangible fixed assets
Land and buildings
Fixtures and fittings
Motor vehicles
Total
£
£
£
£
Cost
At 1 November 2023 and 31 October 2024
49,472
167,512
24,160
241,144
Depreciation and impairment
At 1 November 2023
-
0
101,064
21,009
122,073
Depreciation charged in the year
-
0
13,290
630
13,920
At 31 October 2024
-
0
114,354
21,639
135,993
Carrying amount
At 31 October 2024
49,472
53,158
2,521
105,151
At 31 October 2023
49,472
66,448
3,151
119,071
CLINPHARM PLUS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 6 -
7
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
805,415
719,512
Other debtors
2,267,049
1,734,124
3,072,464
2,453,636
8
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
197,471
191,487
Trade creditors
1,297,628
1,176,984
Corporation tax
153,460
121,190
Other taxation and social security
9,556
24,996
Other creditors
541,914
255,626
2,200,029
1,770,283
9
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
2,200,505
2,410,530

There are charges in favour of Lloyds Bank over the assets of the company.

10
Related party transactions

As at 31 October 2024 the following balances, included in other debtors due within one year, were due from

related companies:

 

Hubco Holdings ASRN Ltd: £131,425

 

Clinpharm Care Ltd: £295,296

 

Washwood Health Healthcare Ltd: £185,186

 

Edgbaston Imaging Centre Ltd: £5,000

 

Meds2you Ltd: £815,482

 

The above balances are repayable on demand.

 

11
Ultimate Controlling Party

The controlling party is Mohammed Azim.

2024-10-312023-11-01falsefalsefalse02 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMohammed AzimSuhail Azim074132372023-11-012024-10-31074132372024-10-31074132372023-10-3107413237core:NetGoodwill2024-10-3107413237core:NetGoodwill2023-10-3107413237core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-3107413237core:FurnitureFittings2024-10-3107413237core:MotorVehicles2024-10-3107413237core:LandBuildingscore:OwnedOrFreeholdAssets2023-10-3107413237core:FurnitureFittings2023-10-3107413237core:MotorVehicles2023-10-3107413237core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3107413237core:CurrentFinancialInstrumentscore:WithinOneYear2023-10-3107413237core:ShareCapital2024-10-3107413237core:ShareCapital2023-10-3107413237core:RetainedEarningsAccumulatedLosses2024-10-3107413237core:RetainedEarningsAccumulatedLosses2023-10-3107413237bus:Director12023-11-012024-10-3107413237core:Goodwill2023-11-012024-10-3107413237core:FurnitureFittings2023-11-012024-10-3107413237core:MotorVehicles2023-11-012024-10-31074132372022-11-012023-10-3107413237core:UKTax2023-11-012024-10-3107413237core:UKTax2022-11-012023-10-3107413237core:NetGoodwill2023-10-3107413237core:NetGoodwill2023-11-012024-10-3107413237core:LandBuildingscore:OwnedOrFreeholdAssets2023-10-3107413237core:FurnitureFittings2023-10-3107413237core:MotorVehicles2023-10-31074132372023-10-3107413237core:LandBuildingscore:OwnedOrFreeholdAssets2023-11-012024-10-3107413237core:CurrentFinancialInstruments2024-10-3107413237core:CurrentFinancialInstruments2023-10-3107413237core:WithinOneYear2024-10-3107413237core:WithinOneYear2023-10-3107413237core:Non-currentFinancialInstruments2024-10-3107413237core:Non-currentFinancialInstruments2023-10-3107413237bus:PrivateLimitedCompanyLtd2023-11-012024-10-3107413237bus:SmallCompaniesRegimeForAccounts2023-11-012024-10-3107413237bus:FRS1022023-11-012024-10-3107413237bus:AuditExemptWithAccountantsReport2023-11-012024-10-3107413237bus:Director22023-11-012024-10-3107413237bus:FullAccounts2023-11-012024-10-31xbrli:purexbrli:sharesiso4217:GBP